Lower mortality of COVID-19 by early recognition and intervention: experience from Jiangsu Province

Annals of Intensive Care

Volumn 10, Issue 1, 2020, Pages

  Sun, Qin ^a   Qiu, Haibo ^a   Huang, Mao ^b   Yang, Yi ^a  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGE; AGED; ARTIFICIAL VENTILATION; BREATHING RATE; CHILD; CHINA; COMPUTER ASSISTED RADIOGRAPHY; CORONAVIRINAE; CORONAVIRUS DISEASE 2019; CORONAVIRUS INFECTION; COVID 19 VIRUS; CRITICALLY ILL PATIENT; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE CONTROL; DISEASE COURSE; DISEASE SEVERITY; EARLY DIAGNOSIS; EARLY INTERVENTION; EPIDEMIC; EXTRACORPOREAL OXYGENATION; FLUID RESUSCITATION; HEART RATE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; INFANT; INTENSIVE CARE UNIT; INTENSIVIST; LETTER; LUNG EDEMA; LUNG INFILTRATE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MEDICAL STAFF; MORTALITY; MORTALITY RATE; NOVEL CORONAVIRUS PNEUMONIA; OXYGEN SATURATION; OXYGEN THERAPY; PATIENT MONITORING; PLEURA EFFUSION; POSITIVE END EXPIRATORY PRESSURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRONE POSITION; RECEIVER OPERATING CHARACTERISTIC; RESOURCE ALLOCATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCREENING; SENSITIVITY AND SPECIFICITY; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; TELECONSULTATION; VERY ELDERLY; VIRUS PNEUMONIA; VIRUS TRANSMISSION; WAKEFULNESS;

EID: 85081963231     PISSN: None     EISSN: 21105820     Source Type: Journal    
DOI: 10.1186/s13613-020-00650-2     Document Type: Letter

References (15)

1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33.
2. Carlos WG, Dela Cruz CS, Cao B, et al. Novel Wuhan (2019-nCoV) coronavirus. Am J Respir Crit Care Med. 2020;201(4):P7–8.
3. Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. 2020;395(10225):689–97.
4. Thompson R. Pandemic potential of 2019-nCoV. Lancet Infect Dis. 2020;20(3):280.
5. Wang FS, Zhang C. What to do next to control the 2019-nCoV epidemic? Lancet. 2020;395(10222):391–3.
6. Kock RA, Karesh WB, Veas F, et al. 2019-nCoV in context: lessons learned? Lancet Planet Health. 2020. 10.1016/S2542-5196(20)30035-8.
7. Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395(10223):e30–1.
8. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473–5.
9. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
10. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020. 10.1001/jama.2020.1585.
11. Guérin C, Reignier J, Richard JC, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013;368(23):2159–68.
12. Liu L, Yang Y, Gao Z, et al. Practice of diagnosis and management of acute respiratory distress syndrome in mainland China: a cross-sectional study. J Thorac Dis. 2018;10(9):5394–404.
13. Arabi YM, Fowler R, Hayden FG. Critical care management of adults with community-acquired severe respiratory viral infection. Intensive Care Med. 2020. 10.1007/s00134-020-05943-5.
14. Xie J, Tong Z, Guan X, et al. Critical care crisis and some recommendations during the COVID-19 epidemic in China. Intensive Care Med. 2020. 10.1007/s00134-020-05979-7.
15. Zhang S, Diao MY, Duan L, et al. The novel coronavirus (SARS-CoV-2) infections in China: prevention, control and challenges. Intensive Care Med. 2020. 10.1007/s00134-020-05977-9.